About Cellectar Biosciences
Cellectar Biosciences (NASDAQ:CLRB) focuses on developing innovative, targeted oncology treatments designed to improve the lives of patients battling cancer. With a keen emphasis on leveraging its proprietary phospholipid drug conjugate™ (PDC) platform, Cellectar aims to create more accurate and efficient therapeutic agents. The company's pipeline includes advanced projects like CLR 131, an investigational radioiodinated PDC therapy undergoing clinical trials for a range of malignancies including multiple myeloma and pediatric cancers. Through these ventures, Cellectar Biosciences is committed to achieving its core objective of advancing cancer treatment options to deliver improved outcomes and hope to patients and their families facing this tough journey.
Snapshot
Operations
Produtos e/ou serviços de Cellectar Biosciences
- CLR 131, an investigational phospholipid drug conjugate for treating multiple myeloma and other hematologic malignancies.
- Pediatric cancer program targeting specific high-risk children's cancers with CLR 131.
- CLR 1900 series, focusing on developing new cancer-targeting compounds.
- CLR 125, a therapeutic for treating micro-metastatic disease in solid tumors.
- PDC platform leveraging proprietary phospholipid ether delivery system for targeted cancer therapy.
- Collaborative research and development partnerships with pharmaceutical companies to expand the application of its technology.
equipe executiva do Cellectar Biosciences
- Mr. James V. CarusoPresident, CEO & Director
- Mr. Chad J. Kolean CPAVP, CFO & Secretary
- Mr. Jarrod LongcorChief Operating Officer